A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Inclusion criteria

• The informed consent had to be signed before any study specific tests or procedures were done
• Healthy male subjects
• Age: 18 to 55 years (inclusive) at the screening examination/visit
• Race: White
• Body mass index (BMI): above/equal 18 and below/equal 29.9 kg/m^2
• Ability to understand and follow instructions

Exclusion criteria

• Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
• Known or suspected liver disorders and bile secretion/flow
• Subjects with thyroid disorders as evidenced by assessment of thyroid stimulating hormone (TSH) levels outside the normal reference range at screening
• Personal or familial history of genetically muscular diseases
• Known hypersensitivity to the study drugs (active substances or excipients of the preparations)
• Known severe allergies e.g. allergies to more than 3 allergens, allergies affecting the lower respiratory tract- allergic asthma, allergies requiring therapy with corticosteroids, urticaria) or significant non-allergic drug reactions
• Known disorders with increased bleeding risk (e.g., periodontosis, hemorrhoids, acute gastritis, peptic ulcer)
• Known sensitivity to common causes of bleeding (e.g. nasal)
• Clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree atrioventricular (AV) block, prolongation of the QRS (QRS interval in ECG) complex over 120 msec or of the QTc-interval over 450 msec at the first screening visit
• Presence or history of arrhythmic disturbances; or known congenital QT (QT interval in ECG) prolongation
• Systolic blood pressure below 100 or above 140 mmHg
• Diastolic blood pressure below 50 or above 90 mmHg
• Heart rate below 50 or above 90 beats/ min